Truist initiated coverage of Carlsmed (CARL) with a Buy rating and $18 price target The firm views Carlsmed as a high growth spine implant company with more predictable alignment and reduced revision rates. The company’s Aprevo is the first U.S. approved personalized spine implant utilizing an artificial intelligence algorithm to address traditional implant limitations, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARL: